9-[4-(氯甲基)苯基]-2,3,6,7,12,13,16,17-八氢-1H，5H，11H，15H-黄原[2,3,4-ij：5,6，7-i'j']diquinolizin-18-chlorium | 167095-09-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 9-[4-(氯甲基)苯基]-2,3,6,7,12,13,16,17-八氢-1H，5H，11H，15H-黄原[2,3,4-ij：5,6，7-i'j']diquinolizin-18-chlorium
• 英文名称: MitoMark Red I
• 英文别名: 16-[4-(chloromethyl)phenyl]-3-oxa-23-aza-9-azoniaheptacyclo[17.7.1.15,9.02,17.04,15.023,27.013,28]octacosa-1(27),2(17),4,9(28),13,15,18-heptaene;chloride
• CAS: 167095-09-2
• 化学式: C32H32Cl2N2O
• 分子量: 531.5
• InChiKey: IKEOZQLIVHGQLJ-UHFFFAOYSA-M

物化性质

• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  1.86
• 重原子数：
  37
• 可旋转键数：
  2
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  15.5
• 氢给体数：
  0
• 氢受体数：
  3

制备方法与用途

生物活性染色

MitoMark Red I 是一种红色的线粒体荧光染色剂，其荧光强度依赖于线粒体膜电位。其激发和发射的最大波长分别为约 578/599 nm。

文献信息

• BIOLOGICALLY ACTIVE COMPOUNDS SPECIFICALLY DELIVERED INTO MITOCHONDRIA
  申请人：MITOTECH SA

  公开号：US20160200749A1

  公开（公告）日：2016-07-14

  This invention relates to biology and medicine and, in particular, can be used in medicine to make a pharmaceutical composition for targeted delivery of biologically active substances into mitochondria, driven by proton electro-chemical potential in the mitochondria. This invention also relates to the method to affect an organism by the targeted delivery of biologically active compounds to mitochondria. The invention can be useful in treatment of diseases or disorders associated with not normal functioning of mitochondria, in particular diseases associated with increased production of free radicals and reactive oxygen species.

  该发明涉及生物学和医学领域，特别是可以用于制备药物组合物，以便通过线粒体内的质子电化学势来实现对生物活性物质的定向输送。该发明还涉及一种通过将生物活性化合物定向输送到线粒体来影响生物体的方法。该发明可用于治疗与线粒体不正常功能相关的疾病或障碍，特别是与自由基和活性氧物质过度产生相关的疾病。
• PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF
  申请人：Lafanechere Laurence

  公开号：US20120041017A1

  公开（公告）日：2012-02-16

  Pyridocarbazole-type compounds of formula (I): are provided as a medicament, and more particularly for application in anticancer chemotherapy. Also provided is a pharmaceutical composition with the compound and methods for preventing and/or treating neurodegenerative-type pathologies, such as Alzheimer's disease and schizophrenia, parasitoses, such as malaria, or glaucomas.

  提供了化学式（I）的吡啶咔唑类化合物作为药物，特别是用于抗癌化疗的应用。还提供了含有该化合物的制药组合物以及预防和/或治疗神经退行性疾病类型，如阿尔茨海默病和精神分裂症，寄生虫病，如疟疾，或青光眼的方法。
• Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
  申请人：UNIWERSYTET LÓDZKI

  公开号：US10022395B2

  公开（公告）日：2018-07-17

  The subject matter of the invention relates to the method of administering the polypropyleneimine dendrimer of the fourth generation, coated with maltotriose, of a general formula I, wherein 25 to 45% of R substituents stand for a maltotriose residue and each of the remaining R substituents is H, to a human subject. The dendrimer of the formula I is designated in short as PPI-G4-OS-Mal-III, where PPI-G4 stands for the 4th generation of polypropyleneimine dendrimer, OS (Open Shell)—for open coat, Mal-III for maltotriose (trisaccharide made of 3 α-glucose residues).

  本发明的主题涉及将通式 I 的第四代聚丙烯亚胺树枝状聚合物（其中 25% 至 45% 的 R 取代基为麦芽三糖残基，其余每个 R 取代基为 H）施用到人体的方法，该树枝状聚合物涂有麦芽三糖。式 I 的树枝状聚合物简称为 PPI-G4-OS-Mal-III，其中 PPI-G4 代表第四代聚丙烯酰亚胺树枝状聚合物，OS（Open Shell）- 代表开放外衣，Mal-III 代表麦芽三糖（由 3 个 α-葡萄糖残基组成的三糖）。
• Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
  申请人：——

  公开号：US20030077826A1

  公开（公告）日：2003-04-24

  A chimeric polypeptide has the formula: pTox-pTarg, wherein pTox is a viral apoptotic peptide, such as the Vpr peptide of HIV-1 or a fragment of the Vpr peptide of HIV-1 containing the amino acid motif H(F/S)RIG that interacts with mitochondrial inner membrane, adenine nucleotide translocation (ANT) protein of a cell. pTarg is an antibody or an antibody fragment that binds to the outer membrane of the cell. Binding of the chimeric polypeptide to the cell is followed by apoptosis of the cell. A vector encoding a chimeric polypeptide and a recombinant host cell comprising the vector are provided. The chimeric polypeptide is useful for targeting pTox to cells, such as cancer cells.

  一种嵌合多肽的分子式为：pTox-pTarg，其中 pTox 是病毒凋亡肽，如 HIV-1 的 Vpr 肽或 HIV-1 的 Vpr 肽的片段，它含有与细胞的线粒体内膜、腺嘌呤核苷酸转位（ANT）蛋白相互作用的氨基酸基序 H(F/S)RIG。嵌合多肽与细胞结合后，细胞会凋亡。本文提供了一种编码嵌合多肽的载体和包含该载体的重组宿主细胞。该嵌合多肽可用于将 pTox 靶向细胞，如癌细胞。
• Screening method and modulators having an improved therapeutic profile
  申请人：——

  公开号：US20030228607A1

  公开（公告）日：2003-12-11

  This invention relates to methods for identifying agents useful for treatment of diseases and pathological conditions affected by nuclear receptors and there associated co-factors, and agents and compositions having an improved therapeutic profile identified using such screening methods.

  本发明涉及鉴定用于治疗受核受体及其相关辅助因子影响的疾病和病理状态的药剂的方法，以及利用这种筛选方法鉴定出的具有改进的治疗特性的药剂和组合物。